Výsledky vyhledávání

Abstract 398: Functional coding and noncoding drivers of EMT-mediated acquired drug resistance

Autor: Scott E. Martin, Richard Bourgon, Christiaan Klijn, Oleg Mayba, Michael R. Costa, Colin K. Watanabe, Siyu Feng, Bob Yauch, Russell Bainer, Eva Lin, Catherine Wilson, Marinella Callow

Publikováno v: Cancer Research. 78:398-398

In response to diverse stimuli, tumor cells can undergo a process resembling the epithelial-mesenchymal transition (EMT) observed during development. During this transition, epithelial-like tumor cells acquire mesenchymal-like physiologic features, b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db43f7d33e1c32c801f2998def5b08ae
https://doi.org/10.1158/1538-7445.am2018-398

Zobrazit plný text záznamu

Abstract 417: A novel predictive biomarker model for MEK sensitivity

Autor: Peter M. Haverty, Mark Merchant, Lukas C. Amler, Bonnie Liu, John Moffat, Christiaan Klijn, Bob Yauch, Marie Wagle, Mark R. Lackner, Shilpi Mahajan, Shih-Min A. Huang, Garret Hampton

Publikováno v: Cancer Research. 76:417-417

KRAS mutations occur in approximately 25% of NSCLC (1). Tumors with these mutations are predicted to be sensitive to MEK inhibition due to activation of MAPK signaling. However, MEK inhibitors in multiple clinical trials, either as a monotherapy or i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::41ad8e639f8edc049187f26bf4e28df8
https://doi.org/10.1158/1538-7445.am2016-417

Zobrazit plný text záznamu

Abstract 2631: Neuregulin-1 expression correlates with sensitivity to the PI3K inhibitor, GDC-0032, outside of PIK3CA mutations in head and neck cancer

Autor: Carol O'Brien, Jeff Settleman, Bob Yauch, Heidi Savage, Mark R. Lackner, Timothy R. Wilson

Publikováno v: Cancer Research. 74:2631-2631

The phosphoinositol-3-kinase (PI3K) signaling pathway is one of the most frequently activated pathways in oncogenesis, and controls critical cellular processes such as proliferation, transcription and survival. GDC 0032 is an orally bioavailable, pot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9406d5f674bd4a51bf7828b606af435
https://doi.org/10.1158/1538-7445.am2014-2631

Zobrazit plný text záznamu

Abstract 1430: Identification of distinct metabolic subtypes within pancreatic ductal adenocarcinoma through broad metabolite profiling

Autor: Marie Evangelista, Bob Yauch, Jeff Settleman, Mark Merchant, Rebecca Hong, Kaska Kowanetz, Jing Qing, Xiangnan Du, Ron McCord, Deepak Sampath, Georgia Hatzivassiliou, Thomas O'Brien, John Moffat, Anneleen Daemen, Min Gao, David A. Peterson, Anna Hitz, Nisebita Sahu, Bonnie Liu

Publikováno v: Cancer Research. 74:1430-1430

Targeting cancer metabolism is currently being evaluated as a potential therapeutic target. Identification of tumor subtypes with specific metabolic requirements will enable the success of such therapies. Using cell line models of pancreatic ductal a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce8c36417938703c891e030ce64dd110
https://doi.org/10.1158/1538-7445.am2014-1430

Zobrazit plný text záznamu

Abstract 1203: Molecular stratification of bladder cancer reveals distinct subtypes associated with unique clinical behaviors

Autor: Doris Kim, Garret Hampton, Rachel Tam, YounJeong Choi, Ling Fu, Lukas C. Amler, Dorothy French, Rajiv Raja, Ilma Abbas, Cheryl Wong, Rajesh Patel, Anna Faarborg, Omar Kabbarah, Erica B. Schleifman, Bob Yauch, Teiko Sumiyoshi

Publikováno v: Cancer Research. 73:1203-1203

Bladder cancer is a common malignancy, and in the US approximately 15,000 patients a year succumb to metastatic disease. The transition from the non-invasive to the lethal invasive variety is poorly understood, and this is reflected by the lack of ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dddbdc44d3d6eb44794a6ceee8671d94
https://doi.org/10.1158/1538-7445.am2013-1203

Zobrazit plný text záznamu

Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors

Autor: Marjorie LaRosiliere, Jiping Zha, Bob Yauch, Rebecca A. Moss, John Bothos, Steve Eppler, Amy C. Peterson, Elayne Wesolowsky, Priti S. Hegde, Mark J. Ratain, David Geary, Wei Yu, Premal Patel, Ravi Salgia

Publikováno v: Cancer Research. 70:2774-2774

COMPLETE RESULTS FROM A PHASE Ia DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF SINGLE-AGENT MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS Background

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5b59f332e48b3165f5dca6448363590
https://doi.org/10.1158/1538-7445.am10-2774

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání